3,3-bis(3-fluorophenyl)propionamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,3-bis(3-fluorophenyl)propionamide
• 英文别名: 3,3-Bis(3-fluorophenyl)propanamide
• 化学式: C₁₅H₁₃F₂NO
• 分子量: 261.271
• InChiKey: BUTSHFFYJOWTLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3,3-bis(3-fluorophenyl)propionic acid 在 吡啶 、 氨 作用下， 以 氯化亚砜 、 乙醚 、 二氯甲烷 、 甲苯 为溶剂， 以25.39 g (81%)的产率得到3,3-bis(3-fluorophenyl)propionamide
  参考文献：
  名称：

  Anticonvulsant and central nervous system-depressing bis(fluorophenyl)alkylamides and their uses

  摘要：

  Bis(Fluorophenyl)alkylamides已经被化学合成，具有有益的药理学特性（如抗癫痫活性），可用于治疗神经系统疾病或障碍，例如癫痫、惊厥和抽搐障碍。发明的首选化合物也几乎不会引起镇静，并且在癫痫动物模型中具有高治疗和保护指数。这些化合物还具有长的药理半衰期，在实际临床治疗应用中，每天一次的剂量应该对患有这些疾病和/或障碍的患者非常有益。这些化合物还可能在中枢和外周神经系统的其他疾病和障碍的治疗中具有进一步的临床效用，或者受其影响的疾病或障碍，包括但不限于痉挛、骨骼肌痉挛和疼痛、不安和压力以及双相情感障碍。

  公开号：

  US06617358B1

文献信息

• Compounds active at a novel site on receptor-operated calcium channels
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US06017965A1

  公开（公告）日：2000-01-25

  Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

  治疗患有神经系统疾病或障碍的患者的方法和组合物，例如中风，头部创伤，脊髓损伤，脊髓缺血，缺血或低氧引起的神经细胞损伤，癫痫，焦虑，由于缺血或低氧引起的神经心理或认知缺陷，例如常见于心脏手术下心肺旁路的后果，或神经退行性疾病，例如阿尔茨海默病，亨廷顿病，帕金森病或肌萎缩性侧索硬化症（ALS）。
• [EN] COUMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES<br/>[FR] COMPOSES AGISSANT SUR UN NOUVEAU SITE DES CANAUX A CALCIUM ACTIVES PAR RECEPTEUR ET UTILES POUR TRAITER DES TROUBLES ET DES MALADIES NEUROLOGIQUES
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：WO1997046511A1

  公开（公告）日：1997-12-11

  (EN) Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).(FR) Procédé et compositions servant à traiter un malade atteint d'une maladie ou de troubles neurologiques, tels qu'une attaque, un traumatisme crânien, une lésion de la moelle épinière, l'ischémie de la moelle épinière, la détérioration des cellules nerveuses provoquée par l'ischémie ou par l'hypoxie, l'épilepsie, l'anxiété, des déficiences neuropsychiatriques ou cognitives dues à l'ischémie ou à l'hypoxie, telles que celles qui apparaissent fréquemment à la suite d'une chirurgie cardiaque sous circulation extra-corporelle, ou des maladies neurodégénératives, telles que la maladie d'Alzheimer, la maladie de Huntington, la maladie de Parkinson ou la sclérose latérale amyotrophique.

  (中) 用于治疗患有神经系统疾病或障碍的患者的方法和组合物，例如中风、头部创伤、脊髓损伤、脊髓缺血、缺血或低氧引起的神经细胞损伤、癫痫、焦虑、由缺血或低氧引起的神经精神或认知缺陷，例如经常作为体外循环下心脏手术后的后果出现的缺血或低氧，或神经退行性疾病，例如阿尔茨海默病、亨廷顿病、帕金森病或肌萎缩侧索硬化症（ALS）。
• Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20020004522A1

  公开（公告）日：2002-01-10

  Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequently occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

  本发明涉及一种用于治疗患有神经系统疾病或障碍的患者的方法和组合物，例如中风、头部创伤、脊髓损伤、脊髓缺血、缺血或缺氧引起的神经细胞损伤、癫痫、焦虑、神经精神或认知缺陷，由于缺血或缺氧而经常发生在心脏手术下心肺转流的后果，或神经退行性疾病，例如阿尔茨海默病、亨廷顿病、帕金森病或肌萎缩侧索硬化症（ALS）。
• Anticonvulsant and central nervous system-depressing bis (fluorophenyl) alkylamides and their uses
  申请人：NPS Pharmaceuticals, Inc.

  公开号：US20030199589A1

  公开（公告）日：2003-10-23

  Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological diseases or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacologic half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

  已经合成了具有有益药理特性（例如，抗惊厥活性）的双（氟苯基）烷基酰胺类化合物，可用于治疗神经系统疾病或障碍，例如癫痫、抽搐和癫痫性疾病。本发明的优选化合物还会引起较少的镇静作用，并在癫痫动物模型中具有高的治疗和保护指数。这些化合物还具有长的药理学半衰期，在实际的临床治疗应用中，应该可以转化为一天一次的剂量，对于患有这些疾病和/或障碍的患者非常有益。这些化合物还可能在治疗中枢和外周神经系统的其他疾病和障碍，或受其影响的疾病和障碍方面具有进一步的临床实用性，包括但不限于痉挛、骨骼肌痉挛和疼痛、不宁腿综合症、焦虑和压力以及双相障碍。
• Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides
  申请人：NPS PHARMACEUTICALS, INC.

  公开号：EP1640359A2

  公开（公告）日：2006-03-29

  Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological disease or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacologic half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

  双(氟苯基)烷基酰胺已被化学合成，具有有益的药理特性（如抗惊厥活性），可用于治疗神经系统疾病或紊乱，如癫痫、抽搐和癫痫发作紊乱等。本发明的优选化合物也几乎不会引起镇静，在癫痫动物模型中具有较高的治疗和保护指数。这些化合物还具有较长的药理半衰期，在实际临床治疗应用中，可实现一天一次给药，对这些疾病和/或失调患者大有裨益。这些化合物在治疗中枢和周围神经系统的其他疾病和失调，或受其影响的疾病或失调，包括但不限于痉挛、骨骼肌痉挛和疼痛、不安腿综合征、焦虑和压力，以及躁郁症等方面，也可能具有进一步的临床效用。